Published in J Infect Dis on January 01, 1991
Multiple gonococcal pilin antigenic variants are produced during experimental human infections. J Clin Invest (1994) 1.93
Interaction of pathogenic neisseriae with nonphagocytic cells. Clin Microbiol Rev (1995) 1.52
Genetic, structural, and antigenic analyses of glycan diversity in the O-linked protein glycosylation systems of human Neisseria species. J Bacteriol (2010) 1.13
Properdin is critical for antibody-dependent bactericidal activity against Neisseria gonorrhoeae that recruit C4b-binding protein. J Immunol (2012) 0.91
Identification of regulatory elements that control expression of the tbpBA operon in Neisseria gonorrhoeae. J Bacteriol (2014) 0.85
Algorithmic assessment of vaccine-induced selective pressure and its implications on future vaccine candidates. Adv Bioinformatics (2010) 0.84
Neisseria gonorrhoeae NspA induces specific bactericidal and opsonic antibodies in mice. Clin Vaccine Immunol (2011) 0.78
The structure, function, synthesis and genetic control of bacterial pili and a molecular model for DNA and RNA transport in gram negative bacteria. Trans N Y Acad Sci (1965) 20.37
Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med (1991) 9.99
Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med (1996) 5.25
Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Shoklo SPf66 Malaria Vaccine Trial Group. Lancet (1996) 4.90
Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med (1997) 4.86
Immunologic response of man to group B meningococcal polysaccharide vaccines. J Infect Dis (1972) 4.54
The properties of sex pili, the viral nature of "conjugal" genetic transfer systems, and some possible approaches to the control of bacterial drug resistance. CRC Crit Rev Microbiol (1971) 4.40
Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med (1982) 4.28
Effect of iron on yields of exotoxin A in cultures of Pseudomonas aeruginosa PA-103. Infect Immun (1978) 4.01
Toxin A-deficient mutants of Pseudomonas aeruginosa PA103: isolation and characterization. Infect Immun (1980) 3.95
In vitro adhesion of Escherichia coli to porcine small intestinal epithelial cells: pili as adhesive factors. Infect Immun (1978) 3.13
Toxin inhibitors of protein synthesis: production, purification, and assay of Pseudomonas aeruginosa toxin A. Methods Enzymol (1979) 3.10
Incidence of exotoxin production by Pseudomonas species. Infect Immun (1977) 3.08
Localization of plasmid loci necessary for the entry of Shigella flexneri into HeLa cells, and characterization of one locus encoding four immunogenic polypeptides. J Gen Microbiol (1987) 3.05
Immunization of suckling pigs against enteric enterotoxigenic Escherichia coli infection by vaccinating dams with purified pili. Infect Immun (1978) 2.94
Role of pili in the adherence of Pseudomonas aeruginosa to injured tracheal epithelium. Infect Immun (1984) 2.92
Mechanical removal of F pili, type I pili, and flagella from Hfr and RTF donor cells and the kinetics of their reappearance. J Bacteriol (1969) 2.87
Antibiotic susceptibility survey of Neisseria gonorrhoeae in Thailand. Antimicrob Agents Chemother (1992) 2.78
Genetic complementation analysis of Escherichia coli type 1 somatic pilus mutants. J Bacteriol (1977) 2.77
Identification and characterization of E. coli type-1 pilus tip adhesion protein. Nature (1988) 2.71
Effect of spectinomycin use on the prevalence of spectinomycin-resistant and of penicillinase-producing Neisseria gonorrhoeae. N Engl J Med (1987) 2.70
Isolation and characterization of Escherichia coli phase variants and mutants deficient in type 1 pilus production. J Bacteriol (1977) 2.67
Iminobiotin affinity columns and their application to retrieval of streptavidin. Proc Natl Acad Sci U S A (1980) 2.57
Lifetime and twelve-month prevalence rates of major depressive episodes and dysthymia among Chinese Americans in Los Angeles. Am J Psychiatry (1998) 2.56
Serologic studies of meningococcal infection and polysaccharide vaccination. J Infect Dis (1971) 2.54
Immunization of suckling pigs against enterotoxigenic Escherichia coli-induced diarrheal disease by vaccinating dams with purified 987 or K99 pili: protection correlates with pilus homology of vaccine and challenge. Infect Immun (1978) 2.52
The Walter Reed staging classification for HTLV-III/LAV infection. N Engl J Med (1986) 2.44
Safety, immunogenicity, and efficacy of live attenuated Vibrio cholerae O139 vaccine prototype. Lancet (1995) 2.43
Seronegative secondary syphilis in a patient infected with the human immunodeficiency virus (HIV) with Kaposi sarcoma. A diagnostic dilemma. Ann Intern Med (1987) 2.35
Persistence of Treponema pallidum following penicillin G therapy. Report of two cases. JAMA (1976) 2.31
Cross-reactivity of Neisseria gonorrhoeae and Neisseria meningitidis and the nature of antigens involved in the bactericidal reaction. J Infect Dis (1974) 2.24
Expression of paragloboside-like lipooligosaccharides may be a necessary component of gonococcal pathogenesis in men. J Exp Med (1991) 2.22
Isolation and characterization of a high-molecular-weight polysaccharide from the slime of Pseudomonas aeruginosa. Infect Immun (1978) 2.22
Protective efficacy of oral whole-cell/recombinant-B-subunit cholera vaccine in Peruvian military recruits. Lancet (1994) 2.16
The importance of the K1 capsule in invasive infections caused by Escherichia coli. J Infect Dis (1984) 2.14
Inhibition of bacterial conjugation by ribonucleic acid and deoxyribonucleic acid male-specific bacteriophages. J Bacteriol (1968) 2.10
Pretreatment with recombinant murine tumor necrosis factor alpha/cachectin and murine interleukin 1 alpha protects mice from lethal bacterial infection. J Exp Med (1989) 2.05
Protective immunity induced in mice by immunization with high-molecular-weight polysaccharide from Pseudomonas aeruginosa. Infect Immun (1978) 2.04
Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. Lancet (1997) 1.94
A general approach to standardization of the solid-phase radioimmunoassay for quantitation of class-specific antibodies. J Immunol Methods (1981) 1.93
Evidence for the role of toxin A in the pathogenesis of infection with Pseudomonas aeruginosa in humans. J Infect Dis (1980) 1.90
Variability of the lytic susceptibility of Neisseria gonorrhoeae to human sera. J Immunol (1977) 1.81
A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity. Vaccine (1995) 1.74
DNA vaccines. Curr Opin Immunol (1996) 1.74
Role of lipopolysaccharide and capsule in the serum resistance of bacteremic strains of Escherichia coli. J Infect Dis (1986) 1.73
Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J Infect Dis (1998) 1.66
Gonococcal pilus vaccine. Studies of antigenicity and inhibition of attachment. J Clin Invest (1981) 1.62
Inhibition of adherence of Neisseria gonorrhoeae by human genital secretions. J Clin Invest (1977) 1.61
Human cytotoxic T lymphocytes against the Plasmodium falciparum circumsporozoite protein. Proc Natl Acad Sci U S A (1991) 1.61
Design and development of pilus vaccines for Haemophilus influenzae diseases. Pediatr Infect Dis J (1989) 1.60
Increased antibiotic resistance of Neisseria gonorrhoeae in Korea. Antimicrob Agents Chemother (1976) 1.58
Choice of bacteria in animal models of sepsis. Infect Immun (1993) 1.51
Quantitative relationship of circulating p24 antigen with human immunodeficiency virus (HIV) RNA and specific antibody in HIV-infected subjects receiving antiretroviral therapy. The RV43 Study Group. J Infect Dis (1995) 1.51
Efficacy trial of a parenteral gonococcal pilus vaccine in men. Vaccine (1991) 1.50
Inflammatory cytokines produced in response to experimental human gonorrhea. J Infect Dis (1995) 1.49
Induced engulfment of Neisseria gonorrhoeae by tissue culture cells. Infect Immun (1988) 1.48
High-molecular-weight polysaccharide antigen from Pseudomonas aeruginosa immunotype 2. Infect Immun (1981) 1.47
Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys. J Infect Dis (1996) 1.45
Effect of race and blood group on the immune response to bacterial polysaccharide and conjugate vaccines. Lancet (1990) 1.41
Safety, immunogenicity, and efficacy in monkeys and humans of invasive Escherichia coli K-12 hybrid vaccine candidates expressing Shigella flexneri 2a somatic antigen. Infect Immun (1992) 1.39
Isolated peripheral tuberculous lymphadenitis in adults: current clinical and diagnostic issues. Clin Infect Dis (1995) 1.39
Purification of the Escherichia coli type 1 pilin and minor pilus proteins and partial characterization of the adhesin protein. J Bacteriol (1988) 1.39
Evaluation of the safety, immunogenicity, and efficacy in healthy adults of four doses of live oral hybrid Escherichia coli-Shigella flexneri 2a vaccine strain EcSf2a-2. Vaccine (1995) 1.38
Syphilis in the AIDS era. N Engl J Med (1987) 1.37
Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites. Am J Trop Med Hyg (1993) 1.34
Use of azithromycin for the treatment of Campylobacter enteritis in travelers to Thailand, an area where ciprofloxacin resistance is prevalent. Clin Infect Dis (1995) 1.34
Specific interaction of the tetragonally arrayed protein layer of Bacillus sphaericus with its peptidoglycan sacculus. J Bacteriol (1979) 1.34
Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans. J Clin Invest (1987) 1.33
Specificity of inhibition of epithelial cell adhesion of Neisseria gonorrhoeae. Infect Immun (1976) 1.33
Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization. Science (1995) 1.33
Experimental human gonococcal urethritis: 250 Neisseria gonorrhoeae MS11mkC are infective. J Infect Dis (1995) 1.32
Identification of the structural gene for F-pilin. J Mol Biol (1976) 1.30
Evolution of human immunodeficiency virus type 1 env sequence variation in patients with diverse rates of disease progression and T-cell function. J Virol (1997) 1.30
Assembly and antigenicity of the Neisseria gonorrhoeae pilus mapped with antibodies. Infect Immun (1996) 1.29
A prospective randomized trial of ofloxacin vs. doxycycline in the treatment of uncomplicated male urethritis. Sex Transm Dis (1989) 1.28
Reactogenicity, immunogenicity and efficacy studies of Escherichia coli type 1 somatic pili parenteral vaccine in man. Scand J Infect Dis Suppl (1982) 1.26
Laboratory and preliminary clinical characterization of Vi capsular polysaccharide-protein conjugate vaccines. Infect Immun (1994) 1.25
A study of particle sizes, shapes and toxicities present in a boivin-type endotoxic preparation. Ann N Y Acad Sci (1966) 1.24
Functions of F pili in mating-pair formation and male bacteriophage infection studies by blending spectra and reappearance kinetics. J Bacteriol (1969) 1.24
Inhibition of clinically significant bacterial organisms in vitro by 2-acetylpyridine thiosemicarbazones. Antimicrob Agents Chemother (1980) 1.23
Meningococcal infections. 3. Studies of group A polysaccharide vaccines. Bull World Health Organ (1971) 1.23
Latex agglutination test for measurement of antibodies to meningococcal polysaccharides. Infect Immun (1972) 1.21
Cholera vaccines: fighting an ancient scourge. Science (1994) 1.21
Isolation, characterization, and in vitro assembly of the tetragonally arrayed layer of Bacillus sphaericus. J Bacteriol (1979) 1.21
Antigenic specificity of antibodies in vaginal secretions during infection with Neisseria gonorrhoeae. J Infect Dis (1980) 1.20